Recently added articles from Worldwide Biotech:
QRXPHARMA/LIAONING NUOKANG MEDICINES TO DEVELOP VENOMICS.
Nov 01, 2009 ... QRxPharma(OTCQX:QRXPY), has announced a strategic alliance with Liaoning Nuokang Medicines Co. Ltd. (Nuokang), a Chinese biopharmaceutical company based in Shenyang, China, to develop and commercialise QRxPharma's venomics assets for the Chinese market. The strategic alliance involves ...
METHYLGENE TO RESUME DEVELOPMENT OF MGCD0103 (MOCETINOSTAT).
Nov 01, 2009 ... MethylGene Inc. (TSX:MYG), Montreal, Quebec. has announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on MGCD0103, the company's proprietary selective histone deacetylase (HDAC) inhibitor for cancer. New patient enrollment in the refractory ...
STEMCELLS, INC. TO ADVANCE CELL-BASED TECHNOLOGIES.
Nov 01, 2009 ... StemCells, Inc. (NASDAQ: STEM). Palo Alto, Calif., has announced organizational initiatives focused on growing its specialty SC ProvenR cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use ...
MALAYSIA DIAGNOSTICS/DEVICES INDUSTRY OUTLOOK FOR 2009.(Industry overview)
Oct 01, 2009 ... Nitin Naik, vice president of the Healthcare, Asia Pacific said that the total Healthcare Expenditure grew at 13.70% CAGR from 2003 to 2008, which stood at US$ 7.6 billion in 2008 (up from US$ 4 billion in 2003). Healthcare expenditure in Malaysia is increasing driven by increased ...
BONE MEDICAL GETS US FDA GUIDANCE ON IND FOR CAPSITONIN.
Oct 01, 2009 ... Bone Medical (ASX:BNE) has received a formal response from the US FDA to the IND application filed in June for Capsitonin(tm), its oral formulation of the approved osteoporosis drug salmon calcitonin. In their response, the FDA has advised that Bone Medical now has an open IND ...